Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Additions at Ezose; Board Changes at HealthLinx


Ezose Sciences this week named Scott Siegel its chief operating officer, a newly created position at the company.

Siegel was previously vice president of business development at the company. Before that he was vice president of corporate development for Redpoint Bio and before that held several positions in business development and marketing at Johnson & Johnson.

Ezose also named Diane McCarthy its director of scientific affairs as well as hired Ezra Jennings as senior scientist and Joshua Alfaro as scientist.

HealthLinx announced the resignations from its board of non-executive directors Stewart Washer and John Chiplin.

Washer joined HealthLinx's board in 2008 and Chiplin in 2010. The company said it would evaluate whether or not to replace them on the board.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.